Expert Interview
A Third View: Discussing Cytokinetics’ FDA Approval of MYQORZO™ (Aficamten) for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Ticker(s): CYTK, BMY, EWTXInstitution: Tufts Medical Center
- Director of the Hypertrophic Cardiomyopathy Center at Tufts Medical Center.
- Research interests involve the role of cardiovascular magnetic resonance (CMR) in the evaluation and management of patients with HCM as well as investigating new therapies to treat the disease.
- Currently the national primary investigator on the first clinical trial evaluating the efficacy of a novel drug for the treatment of HCM symptoms (LIBERTY-HCM). Published more than 100 original scientific articles on HCM in many of the top leading cardiology and medicine journals.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
